AEPCX
Price
$58.34
Change
+$0.18 (+0.31%)
Updated
Jun 6 closing price
Net Assets
133.45B
LAFGX
Price
$15.78
Change
+$0.04 (+0.25%)
Updated
Jun 5 closing price
Net Assets
3.56M
Interact to see
Advertisement

AEPCX vs LAFGX

Header iconAEPCX vs LAFGX Comparison
Open Charts AEPCX vs LAFGXBanner chart's image
American Funds EUPAC C
Price$58.34
Change+$0.18 (+0.31%)
VolumeN/A
Net Assets133.45B
Lord Abbett International Growth F
Price$15.78
Change+$0.04 (+0.25%)
VolumeN/A
Net Assets3.56M
AEPCX vs LAFGX Comparison Chart
Loading...
View a ticker or compare two or three
Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
AEPCX has more cash in the bank: 133B vs. LAFGX (3.56M). LAFGX (0.33) and AEPCX (0.32) have matching dividends . AEPCX was incepted earlier than LAFGX: AEPCX (24 years) vs LAFGX (4 years). LAFGX (9.22) is less costly to investors than AEPCX (1.59). LAFGX is a more actively managed with annual turnover of: 88.00 vs. AEPCX (30.00). LAFGX has a lower initial minimum investment than AEPCX: LAFGX (0) vs AEPCX (250). LAFGX annual gain was more profitable for investors over the last year : 10.39 vs. AEPCX (1.93).
AEPCXLAFGXAEPCX / LAFGX
Total Expense Ratio1.590.70227%
Annual Report Gross Expense Ratio1.599.2217%
Fund Existence24 years4 years-
Gain YTD12.90913.89393%
Front LoadN/AN/A-
Min. Initial Investment2500-
Min. Initial Investment IRAN/AN/A-
Net Assets133B3.56M3,738,055%
Annual Yield % from dividends0.320.3397%
Returns for 1 year1.9310.3919%
Returns for 3 years14.7434.1343%
Returns for 5 years14.63N/A-
Returns for 10 years21.44N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STOK11.140.26
+2.39%
Stoke Therapeutics
APLS19.280.18
+0.94%
Apellis Pharmaceuticals
SNN30.26-0.04
-0.13%
Smith & Nephew plc
CATO2.56-0.07
-2.66%
CATO Corp
GRI1.38-0.05
-3.50%
GRI Bio Inc.